ADAPTIMMUNE THERAPEUTICS PLC Net Change in Cash
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) reported Net Change in Cash of -$65.43 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2025-08-13
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$50.20M.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$3.49M, a 129.46% decline year-over-year.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $11.84M.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$60.41M.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$53.81M, a 243.82% decline from fiscal 2023.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $37.41M.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$42.06M, a 146.64% decline from fiscal 2021.
- ADAPTIMMUNE THERAPEUTICS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $90.18M, a 1271.38% increase from fiscal 2020.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$65.43M 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | -$50.20M 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | -$53.81M 10-K · filed 2025-03-24 | |||
| 2024-09-30 | -$27.59M 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $67.66M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$3.49M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $37.41M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | -$16.53M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | -$29.40M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $11.84M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$42.06M 10-K · filed 2025-03-24 | |||
| 2022-09-30 | -$70.95M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$52.14M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$60.41M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $90.18M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | -$16.85M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$6.40M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$24.45M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $6.58M 10-K · filed 2023-03-06 | |||
| 2020-09-30 | $28.00M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $71.78M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $35.85M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$17.57M 10-K · filed 2022-03-14 | |||
| 2019-09-30 | -$28.75M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$33.50M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$18.09M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$15.82M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $68.95M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | -$41.79M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | -$30.56M 10-Q · filed 2019-05-06 | |||
| 2017-12-31 | -$74.50M 10-K · filed 2019-02-27 | |||
| 2017-09-30 | -$13.24M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | -$36.64M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | $11.81M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$35.98M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | -$54.19M 10-Q · filed 2017-11-02 | |||
| 2015-12-31 | -$30.27M 10-K · filed 2018-03-15 | |||
| 2015-06-30 | $177.87M 10-K · filed 2018-03-15 |